CADTH Canadian Drug Expert Committee recommendation : indication: for the treatment of iron deficiency anemia in adult patients who have intolerance or unresponsiveness to oral iron therapy, the diagnosis must be based on laboratory tests. Iron isomaltoside 1000 (Monoferric-pharmacosmos A/S) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Drug stability.

Physical Description:

1 online resource

Edition:

Version: final.

Place of Publication:

Ottawa, ON : CADTH, 2020.

Summary:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that iron isomaltoside 1000 (Monoferric) be reimbursed for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance of or unresponsiveness to oral iron therapy only if the following conditions are met: Conditions for Reimbursement Prescribing condition 1. The drug must be administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided. Pricing condition 1. Reduced price.

Notes:

Description based on publisher supplied metadata and other sources.